136 related articles for article (PubMed ID: 8850385)
1. 24 hour blood pressure control with once-daily versus twice-daily formulations of diltiazem.
Ruddy TD; Wright JM; Savard D; Handa SP; Chockalingam A; Fischer L; Boulet AP
Cardiovasc Drugs Ther; 1995 Dec; 9(6):799-807. PubMed ID: 8850385
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. The Canadian Multicenter Diltiazem-CD Hypertension Trial Group.
Ruddy TD; Wright JM; Savard D; Handa SP; Chockalingam A; Boulet AP
Cardiovasc Drugs Ther; 1995 Jun; 9(3):413-20. PubMed ID: 8527351
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with a once-daily, extended-release formulation of diltiazem in the treatment of hypertension.
Graney WF
Am J Med; 1992 Aug; 93(2A):56S-64S. PubMed ID: 1519637
[TBL] [Abstract][Full Text] [Related]
4. Sustained antihypertensive activity of diltiazem SR: double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring.
Whelton A; Eff J; Magner DJ
J Clin Pharmacol; 1992 Sep; 32(9):808-15. PubMed ID: 1430300
[TBL] [Abstract][Full Text] [Related]
5. Ambulatory blood pressure profiles in patients treated with once-daily diltiazem extended-release or indapamide alone or in combination.
Prisant LM;
Am J Ther; 2000 May; 7(3):177-84. PubMed ID: 11317166
[TBL] [Abstract][Full Text] [Related]
6. Three-period crossover trial with ambulatory blood pressure monitoring for evaluating antihypertensive therapy.
Meeves S; Hafner K; Park G; Weber M
Am Heart J; 1995 Oct; 130(4):841-8. PubMed ID: 7572595
[TBL] [Abstract][Full Text] [Related]
7. Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product.
White WB; Lacourciere Y; Gana T; Pascual MG; Smith DH; Albert KS
Am Heart J; 2004 Oct; 148(4):628-34. PubMed ID: 15459593
[TBL] [Abstract][Full Text] [Related]
8. Once daily compared with twice daily administration of slow-release diltiazem as monotherapy for hypertension.
Nikkilä M; Inkovaara J; Heikkinen J
Ann Med; 1991 Apr; 23(2):141-5. PubMed ID: 2069791
[TBL] [Abstract][Full Text] [Related]
9. Persistence of anti-hypertensive effect after 'missed doses' of calcium antagonist with long (amlodipine) vs short (diltiazem) elimination half-life.
Leenen FH; Fourney A; Notman G; Tanner J
Br J Clin Pharmacol; 1996 Feb; 41(2):83-8. PubMed ID: 8838433
[TBL] [Abstract][Full Text] [Related]
10. 24-hour efficacy of once-daily diltiazem in essential hypertension.
Massie BM; Der E; Herman TS; Topolski P; Park GD; Stewart WH
Clin Cardiol; 1992 May; 15(5):365-8. PubMed ID: 1623657
[TBL] [Abstract][Full Text] [Related]
11. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: a randomized clinical trial using electronic monitoring.
Leenen FH; Wilson TW; Bolli P; Larochelle P; Myers M; Handa SP; Boileau G; Tanner J
Can J Cardiol; 1997 Oct; 13(10):914-20. PubMed ID: 9374947
[TBL] [Abstract][Full Text] [Related]
12. Antihypertensive efficacy and safe use of once-daily sustained-release diltiazem in the elderly: a comparison with captopril. The Dilcacomp Study Group.
Nicaise J; Neveux E; Blondin P
J Int Med Res; 1995; 23(4):244-53. PubMed ID: 7589767
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group.
Glasser SP; Jain A; Allenby KS; Shannon T; Pride K; Pettis PP; Schwartz LA; MacCarthy EP
Clin Ther; 1995; 17(1):12-29. PubMed ID: 7758054
[TBL] [Abstract][Full Text] [Related]
14. Twenty-four hour ambulatory blood pressure profile of a new slow-release formulation of diltiazem in mild to moderate hypertension.
Dupont AG; Coupez JM; Jensen P; Coupez-Lopinot R; Schoors DF; Hermanns P; Nicolas M
Cardiovasc Drugs Ther; 1991 Aug; 5(4):701-7. PubMed ID: 1888693
[TBL] [Abstract][Full Text] [Related]
15. Antihypertensive efficacy of twice daily controlled release diltiazem using 24 hour intra-arterial blood pressure monitoring.
Sridhara BS; Thomas P; Lahiri A; Raftery EB
Eur J Clin Pharmacol; 1994; 46(5):427-30. PubMed ID: 7957537
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive effect of diltiazem administered once and twice daily.
Mooser V; Waeber B; Nussberger J; Brunner HR
J Hum Hypertens; 1988 Dec; 2(4):257-60. PubMed ID: 3236328
[TBL] [Abstract][Full Text] [Related]
17. Antihypertensive efficacy of optimally titrated doses of once-daily sustained-release diltiazem: a placebo-controlled trial. DILPLACOMP Study Group.
Ollivier JP; Wajman A; Stalla-Bourdillon A
Cardiology; 1995; 86(6):481-7. PubMed ID: 7585759
[TBL] [Abstract][Full Text] [Related]
18. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group.
Fogari R; Ambrosoli S; Corradi L; Degli Esposti E; Mos L; Nami R; Nicrosini F; Pessina AC; Salvetti A; Vaccarella A; Zanchetti A; Martin A; Reeves RA
J Hypertens; 1997 Dec; 15(12 Pt 1):1511-8. PubMed ID: 9431859
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
Hedner T; Himmelmann A
J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
[TBL] [Abstract][Full Text] [Related]
20. Once daily perindopril versus slow release diltiazem in the treatment of mild to moderate essential hypertension. Canadian Study Group on Perindopril.
Can J Cardiol; 1994 Nov; 10 Suppl D():8D-12D. PubMed ID: 7954041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
